Innoviva (INVA) Income from Non-Controlling Interests (2017 - 2022)

Innoviva (INVA) posted Income from Non-Controlling Interests of -$36.2 million for Q3 2022, down 277.06% on a QoQ basis from $20.4 million in Q2 2022, and down 153.45% year-over-year from $67.7 million in Q3 2021.

Innoviva (INVA) Income from Non-Controlling Interests (2017 - 2022) Analysis & Trends

Innoviva's Income from Non-Controlling Interests history runs 6 years deep, the most recent figure standing at -$36.2 million for Q3 2022.

  • Quarterly Income from Non-Controlling Interests fell 153.45% year-over-year to -$36.2 million in Q3 2022, while the trailing twelve-month figure through Sep 2023 was -$36.2 million (down 148.87% YoY) and the FY2022 annual result came in at $6.3 million, down 70.68% from the prior year.
  • Income from Non-Controlling Interests was -$36.2 million for Q3 2022 at Innoviva, down from $20.4 million in the prior quarter.
  • Across five years, Income from Non-Controlling Interests topped out at $67.7 million in Q3 2021 and bottomed at -$36.2 million in Q3 2022.
  • A 5-year average of $12.5 million and a median of $12.7 million in 2019 frame the typical range for Income from Non-Controlling Interests.
  • Annual changes were most pronounced in 2018 — Income from Non-Controlling Interests jumped 4128.68% — and 2022, when it plunged 153.45%.
  • Innoviva's Income from Non-Controlling Interests stood at $5.5 million in 2018, then jumped by 118.39% to $11.9 million in 2019, then jumped by 77.23% to $21.1 million in 2020, then surged by 220.55% to $67.7 million in 2021, then plunged by 153.45% to -$36.2 million in 2022.
  • Business Quant data shows INVA's Income from Non-Controlling Interests at -$36.2 million in Q3 2022, $20.4 million in Q2 2022, and $22.1 million in Q1 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn -
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn -
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn -
9 Revolution Medicines 37.37 Bn 37.37 Bn - -
10 Innoviva 1.59 Bn 983.20 Mn 75.83 Mn -

Historic Data

Download Data
DateValue
Sep 30, 2022 -36.18 Mn
Jun 30, 2022 20.43 Mn
Mar 31, 2022 22.09 Mn
Sep 30, 2021 67.68 Mn
Jun 30, 2021 21.90 Mn
Mar 31, 2021 15.57 Mn
Dec 31, 2020 21.11 Mn
Sep 30, 2020 13.40 Mn
Jun 30, 2020 21.38 Mn
Mar 31, 2020 13.52 Mn
Dec 31, 2019 11.91 Mn
Sep 30, 2019 7.24 Mn
Jun 30, 2019 8.32 Mn
Mar 31, 2019 6.23 Mn
Dec 31, 2018 5.46 Mn
Sep 30, 2018 3.08 Mn
Jun 30, 2018 1.99 Mn
Mar 31, 2018 749,000.00
Dec 31, 2017 129,000.00